Disease risk app can predict your chance of developing dementia

Katherine Davis | December 02, 2016 | Health Exec | Precision Medicine

Interested in knowing your chances of getting dementia? An app can now tell you.

Smartphone app Quealth has been clinically validated for its dementia risk assessment feature, which lets users know their chance of developing the neurological disease.

The free app, available in the App Store and Google Play Store, allows anyone to assess their risk of developing common lifestyle-driven diseases like dementia, cardiovascular disease, diabetes, chronic obstructive pulmonary disease and six forms of cancer, according to a statement from the company. Now, it also can predict the risk of someone developing dementia.

"Quealth's risk algorithm has been optimized and validated to an excellent level of predictive accuracy for dementia" said Paul Nash, Quealth's head of clinical governance, in a statement. "It has a 72 percent chance of distinguishing individuals at risk of developing dementia from those who are not at risk.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

Cardiovascular Business

Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.

Cardiovascular Business

Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business

FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.

Disease risk app can predict your chance of developing dementia

Related Content

Around the web